Nigaĭ S V, Smakhtina O L, Kozbagarova R G, Nigmatullina A A
Vopr Onkol. 1983;29(3):22-6.
A complex clinico-morphological study on the effect of 17-hydroxyprogesterone-capronate was conducted in a group of 75 patients aged 27-69 (stage I-15; stage II-41; stage III-17 and stage IV-2 cases). Total dose for the whole course was 8.0-10.0. All patients underwent surgery after hormonotherapy. Uterine cavity (before and during hormonotherapy) and resected material were examined histologically and cytologically. It was shown that 17-hydroxy-progesterone-capronate is capable of antitumor effect and even complete regression is possible. Most antitumor effect was observed at the initial stages of malignant disease and in cases of well-differentiated tumor. The data obtained may be used in deciding whether 17-hydroxyprogesterone-capronate should be administered in conjunction with other measures or separately.
对75例年龄在27至69岁的患者（I期15例；II期41例；III期17例；IV期2例）进行了一项关于己酸17 - 羟孕酮作用的复杂临床形态学研究。整个疗程的总剂量为8.0 - 10.0。所有患者在激素治疗后均接受了手术。对子宫腔（激素治疗前后）和切除的组织进行了组织学和细胞学检查。结果表明，己酸17 - 羟孕酮具有抗肿瘤作用，甚至可能实现完全消退。在恶性疾病的初始阶段和高分化肿瘤病例中观察到的抗肿瘤作用最为明显。所获得的数据可用于决定己酸17 - 羟孕酮是应与其他措施联合使用还是单独使用。
